Human Anti-NGF Recombinant Antibody (clone mab 911) (CAT#: PABL-286)

Recombinant Human Antibody (mab 911) is capable of binding to NGF, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-NGF mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-NGF mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Preventative muMab 911 attenuates OA pain behaviour but not cartilage damage or synovitis in the MIA model of OA pain.

Figure 1 Preventative muMab 911 attenuates OA pain behaviour but not cartilage damage or synovitis in the MIA model of OA pain.

Rats received weekly subcutaneous injection of 10 mg/kg muMab 911 or PBS on days 0, 7, 14, and 21 post intra-articular injection of MIA or saline. Preventative muMab 911 robustly prevented MIA-induced changes in weight-bearing asymmetry (A, B) and attenuated hindpaw withdrawal thresholds (C, D). Statistical comparison of groups at each timepoint: two-Way ANOVA with Bonferroni's post-hoc tests, *P < 0.05, **P < 0.01, ***P < 0.001: MIA vs saline; #P < 0.05, ##P < 0.01, ###P < 0.001 muMab 911 vs PBS. Note saline muMab 911 group did not differ from the saline PBS group, and is not shown for clarity (n = 10 rats per group). Preventative treatment with muMab 911 did not significantly alter MIA-induced cartilage damage (n = 9–10 per group) (E) or synovial inflammation (n = 8–9 per group) (F). *P < 0.05, **P < 0.01, ***P < 0.001 vs saline-PBS. Comparisons between Areas Under Curve were performed using a Mann–Whitney U-test. Comparisons of histology between groups used a Kruskal Wallis test with Dunn's post hoc. A, C: data are mean ± SEM; B, D, E, F: data are median and interquartile range. M911: muMab 911.

Xu, L., Nwosu, L. N., Burston, J. J., Millns, P. J., Sagar, D. R., Mapp, P. I.,... & Chapman, V. (2016). The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and cartilage, 24(9), 1587-1595.

Figure 2 Preventative muMab 911 and cartilage damage or synovitis in the MIA model of OA pain.

Figure 2 Preventative muMab 911 and cartilage damage or synovitis in the MIA model of OA pain.

Histological sections of osteochondral (A–C) or synovial (D–F) tissue. A; PBS-treated saline-injected control showing an intact joint with smooth cartilage, normal joint margin and chondrocyte morphology. B; 1 mg MIA-injected PBS-treated rat showing OA structural pathology: cartilage damage (green arrows); chondrocyte loss (green arrows); subchondral bone changes (asterisk). C: M911-treated MIA-injected rat exhibited similar pathology to the MIA-PBS treated rat (B). D: 1–2 cell deep synovial lining layer (blue arrow) in PBS-treated saline-injected control. E; Synovial hyperplasia (red arrows) in 1 mg MIA-injected PBS-treated rat. F: Synovium from a M911-treated MIA-injected rat exhibited similar pathology to the MIA-PBS treated rat (E). Photomicrographs show haematoxylin and eosin stained sections of knee tissue from a rat with the median pathology score from each group. Scale bars = 200 μm. F = femur, m = meniscus, c = cartilage, t = tibia, sb = subchondral bone and s = synovium.

Xu, L., Nwosu, L. N., Burston, J. J., Millns, P. J., Sagar, D. R., Mapp, P. I.,... & Chapman, V. (2016). The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and cartilage, 24(9), 1587-1595.

Figure 3 Preventative and therapeutic muMab 911 attenuates the number of TRAP positive osteoclasts in the tibial plateau in MIA rats.

Figure 3 Preventative and therapeutic muMab 911 attenuates the number of TRAP positive osteoclasts in the tibial plateau in MIA rats.

(A) The number of TRAP positive osteoclasts in the tibial plateau was significantly increased in MIA rats receiving vehicle treatment. Preventative treatment with muMab 911 significantly reduced the number of TRAP positive osteoclasts in MIA rats. Data are mean ± SEM, n = 9–10 per group. (B) Therapeutic muMab 911 significantly attenuated the MIA-induced increase in the number of TRAP positive osteoclasts in the tibial plateau. Data are mean ± SEM n = 8–10 per group. Statistical comparison was carried out using one-Way ANOVA with Bonferroni's post-hoc tests, *P < 0.05, **P < 0.01. Representative images of osteoclasts at the osteochondral junction of the tibial plateau in a saline-PBS rat (left), MIA-PBS rat (middle) and MIA-muMab 911 rat (right) in the preventative study (C) and therapeutic study (D). Images were taken with a Zeiss Axioplan microscope at 10× magnification. Arrows indicate multinucleated TRAP positive osteoclasts. M911: muMab 911.

Xu, L., Nwosu, L. N., Burston, J. J., Millns, P. J., Sagar, D. R., Mapp, P. I.,... & Chapman, V. (2016). The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and cartilage, 24(9), 1587-1595.

Figure 4 Therapeutic muMab 911 attenuates established OA pain behaviour but not cartilage damage and synovitis in the MIA model of OA pain.

Figure 4 Therapeutic muMab 911 attenuates established OA pain behaviour but not cartilage damage and synovitis in the MIA model of OA pain.

Rats received subcutaneous injection of 10 mg/kg muMab 911 or PBS on days 14 and 21 post intra-articular injection of MIA. muMab 911 treatment alleviated MIA-induced changes in weight-bearing asymmetry (A, B) and attenuated hindpaw withdrawal thresholds (C, D). Statistical comparison of muMab 911 and PBS treatment on pain behaviour, A, C are mean ± SEM (n = 8–10 rats per group): two-Way ANOVA with Bonferroni's post-hoc tests, #P < 0.05, ###P < 0.001. Note behavioural data from rats which received intra-articular injection of saline were comparable to the preventative study, and are not shown for clarity. B, D are median and interquartile range, comparison of these data was performed with a Mann–Whitney U-test, #P < 0.05, ##P < 0.01. Therapeutic treatment with muMab 911 did not significantly alter MIA-induced cartilage damage (E) or synovial inflammation (F) (n = 8–10 rats per group). E, F are median and interquartile range, comparisons between groups used a Kruskal Wallis test with Dunn's post hoc comparison. *P < 0.05, **P < 0.01, ***P < 0.001. M911: muMab 911.

Xu, L., Nwosu, L. N., Burston, J. J., Millns, P. J., Sagar, D. R., Mapp, P. I.,... & Chapman, V. (2016). The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and cartilage, 24(9), 1587-1595.

Figure 5 Shows that anti-NGF MAbs inhibited binding of hNGF to a TrkA-IgG receptor immunoadhesin.

Figure 5 Shows that anti-NGF MAbs inhibited binding of hNGF to a TrkA-IgG receptor immunoadhesin.

Figure 6 Shows the ability of anti-NGF MAbs to inhibit binding of hNGF to a p75-IgG immunoadhesin.

Figure 6 Shows the ability of anti-NGF MAbs to inhibit binding of hNGF to a p75-IgG immunoadhesin.

Figure 7 Shows the ability of anti-NGF MAbs to inhibit binding of hNGF to the TrkA extracellular domain expressed on transfected CHO cells. Inhibition of tyrosine phosphorylation was measured by ELISA using an antiphophotyrosine MAb.

Figure 7 Shows the ability of anti-NGF MAbs to inhibit binding of hNGF to the TrkA extracellular domain expressed on transfected CHO cells. Inhibition of tyrosine phosphorylation was measured by ELISA using an antiphophotyrosine MAb.

Figure 8 Shows that treatment with anti-NGF MAb 911 blocks NGF induced thermal hyperalgesia.

Figure 8 Shows that treatment with anti-NGF MAb 911 blocks NGF induced thermal hyperalgesia.


Specifications

  • Immunogen
  • Human nerve growth factor (beta polypeptide)
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • Human IgG
  • Specificity
  • Human NGF
  • Species Reactivity
  • Human
  • Clone
  • mab 911
  • Applications
  • WB, ELISA, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • NGF; nerve growth factor (beta polypeptide); NGFB; HSAN5; Beta-NGF; beta-nerve growth factor; nerve growth factor; beta subunit

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone mab 911"

See other products for "Ngf"

Human Antibody

Humanized Antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0852MZ Chicken Anti-NGF Polyclonal IgY ELISA Chicken antibody
BRD-1134MZ Chicken Anti-Beta NGF Polyclonal IgY ELISA, WB, IHC Chicken antibody

Rabbit Monoclonal Antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-1768CQ Recombinant Mouse Anti-NGF Antibody (aD11) IF, BL, ELISA, IHC IgG1, κ
NEUT-1772CQ Recombinant Mouse Anti-NGF Antibody (25623.1) Dot, ELISA, Inhib IgG1

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-025ML Afuco™ Anti-NGF ADCC Recombinant Antibody (Frunevetmab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody
AFC-TAB-031ML Afuco™ Anti-NGF ADCC Recombinant Antibody (Ranevetmab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody
AFC-TAB-111 Afuco™ Anti-NGF ADCC Recombinant Antibody (Tanezumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-110 Afuco™ Anti-NGF Recombinant Antibody (AFC-TAB-110), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF Human IgG1, κ

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-286. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare